Document is current

Article History

Received: 3 February 2018

Accepted: 6 June 2018

First Online: 4 July 2018

Ethics approval and consent to participate

: The original trial providing data for this analysis was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human patients were approved by the Ethics Review Committee of the Sydney South West Area Health Service, NSW, Australia (ref. X07-0089); the Ethical Committee of the Faculty of Medicine of the Technical University of Munich, Germany (ref. 1812/07); and Nottingham Research Ethics Committee, UK (ref: 07/Q2404/40). Written informed consent was obtained from all study participants.

: Not applicable.

: SAJ and ALA have received further research funding from Weight Watchers International Inc. to support a publicly funded trial. SAJ has a research grant from the Cambridge Weight Plan and has conducted a study in which the intervention was provided free of charge by Slimming World. IDC and NRF have received research grants for other clinical trials funded by NovoNordisk, MSD, and GlaxoSmithKline. IDC has received payment for lectures from Novo Nordisk, Servier Laboratories (Australia) and Ache Pharmaceuticals, and an honorarium for chairing the steering committee of the ACTION IO study. HH has received a travel grant from Roche; acted as PI of a clinical study for Riemser Pharma; is on the Advisory Board for Novo Nordisk, Orexigene, Boehringer Ingelheim, Weight Watchers International Inc.; and has received payment for lectures from Sara Lee, Lilly, Novartis, Sanofi-Aventis, and Bristol-Myers Squibb. GLA, IST and CH declare no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.